Clinical trials
Generalized Myasthenia Gravis clinical trials
Below are recruiting generalized myasthenia gravis clinical trials, each written for real people, not researchers. We’re tracking 67 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05067348RecruitingPhase 2
Tocilizumab for generalized myasthenia gravis symptoms
This trial tests whether tocilizumab can improve symptoms and safety in people with generalized myasthenia gravis (MG) who already take standard MG treatments. It may help if your weakness is still significant despite current therapy.
Beijing, Beijing MunicipalityAges 18–80 - NCT05214612Recruiting
Predictors of outcomes in myasthenia gravis
This study looks at what helps predict outcomes in people with myasthenia gravis (MG). It may help doctors better forecast how MG will progress and which factors matter most for recovery and long-term health.
AsyutAges 16 years+ - NCT05337891Recruiting
Evening vs morning nerve testing in myasthenia gravis
This study compares how well a nerve test works when done in the evening versus in the morning for people with myasthenia gravis. It may help doctors choose the best time to test nerve fatigue and better measure disease activity.
Krakow, Lesser Poland VoivodeshipAges 18–80 - NCT05868837RecruitingPhase 3
Rituximab for myasthenia gravis in people with moderate symptoms
This Phase 3 trial tests rituximab (an immune system medicine) to see if it improves myasthenia gravis (MG) symptoms and function. It’s for adults with confirmed MG and moderate-to-severe impact on daily activities despite current care.
RomaAges 18 years+ - NCT06055959RecruitingPhase 2/Phase 3
Zilucoplan for children with generalized myasthenia gravis
This study tests a new daily shot (zilucoplan) for children and teens with generalized myasthenia gravis (gMG), a condition that causes muscle weakness. It aims to see if the drug is safe and helps improve strength and daily functioning.
Chicago, IllinoisAges 12–17 - NCT06064695Recruiting
Electrical muscle stimulation exercise for myasthenia gravis
This study tests if whole-body electrical muscle stimulation exercise can help adults with generalized myasthenia gravis. It also enrolls healthy controls for comparison. If you have MG and can stand for about 15 minutes, this may be an option.
Fairway, KansasAges 18 years+ - NCT06371040RecruitingPhase 1
CAR-T cell therapy for severe myasthenia gravis
This trial is testing a new type of cell therapy called CAR-T that targets two proteins (CD19 and BCMA) on certain immune cells. It aims to help people with severe myasthenia gravis that has not improved with standard treatments.
Xi'an, ShaanxiAges 18–80 - NCT06392386RecruitingPhase 2/Phase 3
Efgartigimod for children with generalized myasthenia gravis
This study tests an investigational drug called efgartigimod for children and teens with generalized myasthenia gravis. It may help those who haven't responded well enough to standard treatments.
Charlotte, North CarolinaAges 2–17 - NCT06456580RecruitingPhase 3
Telitacicept for generalized myasthenia gravis
This trial tests a new medication called Telitacicept for people with generalized myasthenia gravis (gMG). The goal is to see if it can reduce muscle weakness and improve daily function. You may be able to join if you have moderate to severe symptoms and have not had recent thymoma or other serious health issues.
Scottsdale, ArizonaAges 18 years+ - NCT06987539RecruitingPhase 2
Inebilizumab for children with generalized myasthenia gravis
This study tests if an investigational drug called inebilizumab is safe and helpful for children with generalized myasthenia gravis (gMG). It is for children ages 2 to 17 who have certain antibodies or typical symptoms of gMG and are already on stable treatment.
Austin, TexasAges 2–17 - NCT06491238Recruiting
Light vs. moderate exercise for myasthenia gravis
This study compares light exercise (like gentle walking) to moderate exercise (like brisk walking) for people with myasthenia gravis. It aims to see if one type of exercise is safer and more helpful for managing symptoms.
Saint Paul, MinnesotaAges 18–80 - NCT06587867RecruitingPhase 3
Efgartigimod for seronegative myasthenia gravis
This study tests an experimental drug called efgartigimod (given through an IV) for people with a rare type of myasthenia gravis that doesn't show up on standard antibody tests. It aims to see if the drug can improve muscle weakness and daily function.
Toronto, OntarioAges 18 years+ - NCT06193889RecruitingPhase 2/Phase 3
Car-t cell therapy for generalized myasthenia gravis
This trial tests a new cell therapy (CAR-T cells) for people with generalized myasthenia gravis. It aims to reduce symptoms and improve daily life by targeting and destroying faulty immune cells.
Los Angeles, CaliforniaAges 18–75 - NCT07647510RecruitingPhase 3
Testing Claseprubart for Generalized Myasthenia Gravis
This study tests whether a new drug called claseprubart can help adults with generalized myasthenia gravis (a condition where muscles get weak and tired easily). The drug works by targeting part of the immune system that damages muscles.
Fayetteville, North CarolinaAges 18–80 - NCT06607627RecruitingPhase 3
Testing gefurulimab in children with generalized myasthenia gravis
This study tests a new drug called gefurulimab in children and teens with generalized myasthenia gravis (a disease that causes muscle weakness). It looks at how safe and effective the drug is, and how it works in the body.
Washington D.C., District of ColumbiaAges 6–17 - NCT06617741Recruiting
Global Registry for Myasthenia Gravis Patients
This trial is a global registry for people with myasthenia gravis (MG). It collects information to help researchers better understand MG and improve care.
Westborough, MassachusettsAges 18 years+ - NCT06704269RecruitingPhase 1/Phase 2
YTB323 for treatment-resistant generalized myasthenia gravis
This trial tests a new CAR-T cell therapy (YTB323) for people with generalized myasthenia gravis that hasn't been well-controlled by standard treatments. The goal is to see if it can safely improve symptoms and change how the immune system attacks the nerves.
Orange, CaliforniaAges 18–65 - NCT06435312Enrolling by invitationPhase 3
Studying zilucoplan for children with generalized myasthenia gravis
This study gives an injectable medicine called zilucoplan to children who were part of an earlier trial and could benefit from more treatment. It aims to see if zilucoplan is safe and helpful for young patients with generalized myasthenia gravis.
MilanAges 12 years+ - NCT06909253Recruiting
Study of ravulizumab for generalized myasthenia gravis
This study looks at how well ravulizumab works for people with generalized myasthenia gravis (gMG) who have not tried complement inhibitors before. The goal is to see if this treatment helps improve symptoms in everyday life.
BydgoszczAges 18 years+ - NCT06967480Recruiting
Early ravulizumab for recent-onset generalized myasthenia gravis
This trial tests an early treatment with ravulizumab (a medication that blocks part of the immune system) for people who have recently developed moderate-to-severe generalized myasthenia gravis. The goal is to see if starting treatment early can improve symptoms and daily life.
BergamoAges 18 years+ - NCT07058298RecruitingEarly Phase 1
GC012F injection for hard-to-treat myasthenia gravis
This study tests an investigational drug called GC012F for people with generalized myasthenia gravis (gMG) that hasn't improved with standard treatments. The goal is to see if it can reduce symptoms and improve daily life.
Wuhan, HubeiAges 18–75 - NCT07072988RecruitingPhase 4
Steroid reduction with efgartigimod in older adults with generalized myasthenia gravis
This trial tests if a new drug called efgartigimod can help older adults with generalized myasthenia gravis safely reduce their steroid dose. The goal is to manage the disease with fewer steroid side effects.
Nice, Alpes-MaritimesAges 65 years+ - NCT07215650RecruitingPhase 1
Cizutamig for generalized myasthenia gravis
This trial tests an investigational drug called cizutamig for people with generalized myasthenia gravis (gMG) whose symptoms are not well controlled by current treatments. The goal is to see if it can improve daily activities.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07221838RecruitingPhase 4
Steroid Tapering Study for Myasthenia Gravis on Ravulizumab
This study is for people with generalized myasthenia gravis who are already on ravulizumab and a daily steroid. It aims to see if the steroid dose can be safely lowered over time.
Chicago, IllinoisAges 18 years+
Hear when a new Generalized Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for generalized myasthenia gravis?
- Yes. Clin2 currently lists 67 recruiting generalized myasthenia gravis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a generalized myasthenia gravis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a generalized myasthenia gravis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.